<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

        <link rel="stylesheet" href="assets/css/bootstrap.min.css">
    <link rel="stylesheet" href="assets/css/style.css">

    <title>Omnitrope</title>
</head>

<body>
    <header>
        <div class="py-4 mt-3">
            <div class="container py-1">
                <div class="d-flex justify-content-between align-items-end">
                    <a href="index.html">
                        <img src="assets/images/logo.svg" alt="logo">
                    </a>
                    <div class="d-none d-lg-block text-uppercase text-gray text-center">
                        <a href="#">
                            FR
                        </a>
                        <span>
                            |
                        </span>
                        <a href="#" class="login-logout">
                            logout
                        </a>
                    </div>
                    <div class="d-lg-none">
                        <svg viewBox="0 0 24 24" fill="#E21932" height="24" width="24">
                            <path d="M3 18h18v-2H3v2zm0-5h18v-2H3v2zm0-7v2h18V6H3z"></path>
                        </svg>
                    </div>

                </div>
            </div>
        </div>
        <nav class="bg-red font-weight-semibold d-lg-flex">
            <div class="mx-auto justify-content-between flex-grow-1 d-lg-flex">
                <a href="surepal.html">
                    SurePal<sup>®</sup>
                </a>
                <a href="important-safty-information.html">
                    Important Safety Information
                </a>
                <a href="resources.html">
                    Resources
                </a>
            </div>
            <a href="omnisource.html" class="bg-violet">
                OmniSource<sup>™</sup> Patient Support Program
            </a>
        </nav>
    </header>

    <section class="isi-content">
        <div class="container text-gray">
            <h2 class="big-title font-weight-bold">
                Important Safety Information
            </h2>
            <div class="mb-3">
                <p class="font-weight-bold text-decoration-underline">
                    Indications and clinical use:
                </p>
                <p>
                    <sup>Pr</sup>Omnitrope<sup>®</sup> (somatropin for injection) is indicated for:
                </p>
            </div>
            <div class="mb-3">
                <p class="font-weight-bold">
                    Children
                </p>
                <p>
                    The long-term treatment of children, who have growth failure due to an inadequate secretion of
                    endogenous growth hormone (growth hormone deficiency [GHD]). Other causes of short stature should be
                    excluded.
                </p>
            </div>
            <div class="mb-3">
                <p class="font-weight-bold">
                    SGA Indication
                </p>
                <p>
                    Omnitrope<sup>®</sup> is indicated for the treatment of growth failure (current height standard
                    deviation score [SDS] &lt;-2) in short children born SGA (birth weight and/or length below -2 SD)
                    and who fail to achieve catch-up growth (height velocity SDS &lt;0 during the last year) by 2 to 4
                    years or later.
                </p>
            </div>
            <div class="mb-3">
                <p class="font-weight-bold">
                    TS Indication
                </p>
                <p>
                    The treatment of short stature associated with Turner syndrome in patients whose epiphyses are not
                    closed.
                </p>
            </div>
            <div class="mb-3">
                <p class="font-weight-bold">
                    ISS Indication
                </p>
                <p>
                    The long-term treatment of idiopathic short stature (ISS), also called non-growth hormone-deficient
                    short stature, defined by height standard deviation score (SDS) <-2.25, and associated with growth
                        rates unlikely to permit attainment of adult height in the normal range, in pediatric patients
                        for whom diagnostic evaluation excludes other causes associated with short stature that should
                        be observed or treated by other means. Omnitrope® treatment for ISS should be prescribed only
                        for those patients whose epiphyses are not closed. </p>
            </div>
            <div class="mb-3">
                <p class="font-weight-bold">
                    Adults
                </p>
                <p>
                    Omnitrope<sup>®</sup> (somatropin [rDNA origin] for injection) is indicated for replacement of
                    endogenous growth hormone in adults with growth hormone deficiency who meet either of the following
                    two criteria:
                </p>
                <p>
                    <u>Adult Onset (AO):</u> Patients who have growth hormone deficiency, either alone or associated
                    with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic
                    disease, surgery, radiation therapy, or trauma; or
                </p>
                <p>
                    <u>Childhood Onset (CO):</u> Patients who were growth hormone deficient during childhood as a result
                    of congenital, genetic, acquired, or idiopathic causes.
                </p>
            </div>
            <p class="mb-3">
                Patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses
                are closed should be re-evaluated before continuation of somatropin therapy at the reduced dose level
                recommended for growth hormone deficient adults.
            </p>
            <div class="mb-3">
                <p>
                    <u>
                        <b>Contraindications:</b>
                    </u>
                </p>
                <ul>
                    <li class="d-flex align-items-start">
                        <span>•</span>Patients with acute critical illness suffering complications following open heart
                        surgery,
                        abdominal
                        surgery, multiple accidental trauma, acute respiratory failure or similar
                        conditions should not be treated with somatropin.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>
                        <span>
                            Growth hormone is contraindicated in children with <b>
                                Prader-Willi Syndrome
                            </b> who are
                            severely obese or
                            have severe respiratory impairment.
                        </span>
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>
                        <span>
                            Omnitrope<sup>®</sup> should not be used for growth promotion in pediatric patients with
                            closed
                            epiphyses; in
                            patients with any evidence of neoplastic activity; or in newborns or patients
                            with a known sensitivity to benzyl alcohol (5 mg/1.5 mL only), somatropin, or to any other
                            ingredient in
                            the formulation.
                        </span>
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Omnitrope<sup>®</sup> should not be administered in patients with proliferative or
                        preproliferative diabetic
                        retinopathy.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>
                        <span>
                            <b>
                                Renal transplantation:
                            </b> Treatment with Omnitrope® should be discontinued at the
                            time of
                            renal
                            transplantation.
                        </span>
                    </li>
                </ul>

            </div>
            <div class="mb-3">
                <p>
                    <u><b>Most serious warnings and precautions:</b></u>
                </p>
                <p>
                    <b>
                        Prader-Willi Syndrome:
                    </b> There have been reports of fatalities associated with the use of growth hormone in pediatric
                    patients with Prader-Willi syndrome who have one or more
                    of the following risk factors: severe obesity, history of respiratory impairment or sleep apnea, or
                    unidentified respiratory infection.
                </p>
                <p>
                    <b>Patients with acute critical illness:</b> A significant increase in mortality was reported among
                    somatropin
                    treated patients with acute critical illness in intensive care units due to complications following
                    open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
                    compared
                    with those receiving placebo.
                </p>
                <p>
                    <b>
                        Antibody production:
                    </b> Any change in brand of somatropin products should be made cautiously and only under
                    medical supervision.
                </p>

            </div>
            <div class="mb-3">
                <p>
                    <u>
                        <b>Other relevant warnings and precautions:</b>
                    </u>
                </p>
                <ul>
                    <li class="d-flex align-items-start">
                        <span>•</span>Carcinogenesis and mutagenesis, due to increased risk of developing neoplasm with
                        growth hormone
                        treatment.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Need for periodic thyroid function tests in patients with Turner Syndrome.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Dependence/tolerance.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Serious AE risks associated with congenital disorders.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Endocrine and metabolism: patients with diabetes mellitus, glucose intolerance,
                        and
                        hypopituitarism should be monitored closely while on therapy.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Endocrine and metabolism: patients with diabetes mellitus, glucose intolerance,
                        and
                        hypopituitarism should be monitored closely while on therapy.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Thyroid function should be evaluated before starting somatropin therapy and should
                        be monitored
                        regularly during treatment, not less frequently than annually.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Risk of reduction of serum cortisol concentrations.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Risk of unmasking secondary hypoadrenalism.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span> Fluid retention.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span> Hematologic: Insulin-like Growth Factor-I (IGF-I) concentrations should be
                        monitored regularly.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Intracranial hypertension.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Local or systemic allergic reactions (antibody testing should be considered).
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Musculoskeletal.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Neurologic: Growth hormone deficiency secondary to an intracranial lesion should
                        be examined
                        frequently for progression or recurrence of the underlying disease process.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Patients taking oral estrogen.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Pancreatitis.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Prader-Willi syndrome.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Secondary neoplasm in survivors of childhood cancer.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Turner syndrome patients and the risk of otitis media and other ear disorders,
                        cardiovascular
                        disorders, and autoimmune thyroid disease.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Injection site should be rotated daily to help prevent lipoatrophy.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Obese individuals are more likely to manifest adverse effects when treated with a
                        weight-based
                        regimen.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Evaluate pediatric patients with onset of a limp or complaints of hip or knee
                        pain; risk of
                        slipped capital femoral epiphysis.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>Pregnant and nursing women.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>
                        Prudence is indicated for children &lt;3 years of age.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>
                        Adult patients should be monitored for
                        adverse events, IGF-1 levels and other parameters of GH response.
                    </li>
                    <li class="d-flex align-items-start">
                        <span>•</span>
                        Children should be monitored
                        with measurement of IGF-1/IGFBP-3 levels and assessed for height increase and velocity.
                    </li>
                </ul>

            </div>
            <div class="mb-3">
                <p>
                    <u>
                        <b>
                            For more information:
                        </b>
                    </u>
                </p>
                <p>
                    Please consult the <u class="text-red">Product Monograph</u> for important information relating to adverse reactions, drug interactions and dosing information which have not been discussed in this piece.
                </p>

            </div>
            <p>
                The Product Monograph is available by calling 1-877-343-OMNI.
            </p>
        </div>
    </section>

    <footer>
        <div class="pt-3 mb-5 pb-xl-4">
            <div class="footer-top pt-3">
                <div
                    class="container d-flex flex-column flex-xl-row align-items-center align-items-xl-end justify-content-between">
                    <div class="d-flex mt-5 order-3 order-xl-0 justify-content-between">
                        <img src="assets/images/footer/1.svg" alt="">
                        <img src="assets/images/footer/2.svg" alt="">
                    </div>
                    <div class="text-center text-xl-end mt-3 mt-xl-0">
                        <div class="font-weight-semibold">
                            <a href="#">
                                Contact Sandoz
                            </a>
                            <span>
                                |
                            </span>
                            <a href="#">
                                Privacy Policy
                            </a>
                            <span>
                                |
                            </span>
                            <a href="#">
                                Terms and Conditions
                            </a>
                        </div>
                        <p class="mt-4 pt-xl-3">
                            &copy; 2022 Sandoz Canada Inc. All rights reserved., 110, rue de Lauzon, Boucherville (QC),
                            J4B
                            1E6,
                            Canada.
                        </p>
                        <p class="mt-1">
                            Omnitrope<sup>®</sup>, OmniSource<sup>™</sup>, SurePal® and the Sproutz<sup>®</sup> are
                            trademarks used under
                            license by Sandoz
                            Canada Inc.
                        </p>
                    </div>
                </div>
            </div>
        </div>
        <div class="footer-bottom bg-violet">
            <div class="container d-flex flex-column flex-xl-row align-items-center justify-content-between">
                <p class="text-white font-weight-semibold text-center text-xl-start">
                    Remind your patients to download and explore the OMNIPAL<sup>TM</sup> app!
                </p>
                <div>
                    <a href="#">
                        <img src="assets/images/footer/google-play.svg" alt="">
                    </a>
                    <a href="#">
                        <img src="assets/images/footer/app-store.svg" alt="">
                    </a>
                </div>
            </div>
        </div>
    </footer>



    <script src="assets/js/index.js"></script>
</body>

</html>